AstraZeneca’s FluMist approval for self-administration could increase flu vaccine uptake: GlobalData
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...
The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...
The FDA has approved at-home self- or caregiver-administration of FluMist (influenza vaccine live, intranasal).
AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...
The US Food and Drug Administration (FDA) has approved AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for self-administration. The approval makes FluMist the only 'flu vaccine ...
FluMist, a needle-free nasal spray influenza vaccine, has been approved by the FDA for self-administration in the US, making ...
AstraZeneca’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and ...
FluMist has been sold at pharmacies for years, but now it will be available to use at home as early as next year.
Pharmaceutical Technology on MSN3d
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPAThe EMA CHMP has recommended granting approval for AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis ...
The FDA has approved FluMist (AstraZeneca) for self-administration by adults up to age 49 years or for caregiver administration for children aged 2 to 17 years, making it the first self-administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback